Treatment of Postoperative Hypoparathyroidism Using Cultured Allogenic Parathyroid Cells
NCT ID: NCT05186883
Last Updated: 2022-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
20 participants
INTERVENTIONAL
2022-03-01
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sternal Closure With Biologic Bone Cement in Patients Undergoing Coronary Artery Bypass Grafting (CABG)
NCT01261858
Parathyroid Allo-transplantation With a New Technique
NCT02134483
Effect of Parathyroidectomy on Cardiovascular Health
NCT02989428
Integration of Minimal Invasive Cardiopulmonary Bypass System and the Research of Its Blood Compatibility
NCT04476342
A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume
NCT00816023
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment with allogenic parathyroid cells
Patients with postoperative hypoparathyroidism receiving standard treatment and allogenic parathyroid cells
Allogenic parathyroid cells
Allogenic parathyroid cells
Standard treatment according to the Clinical protocols
Standard treatment of postoperative hypoparathyroidism according to the Clinical protocols
Control
Patients with postoperative hypoparathyroidism receiving standard treatment
Standard treatment according to the Clinical protocols
Standard treatment of postoperative hypoparathyroidism according to the Clinical protocols
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Allogenic parathyroid cells
Allogenic parathyroid cells
Standard treatment according to the Clinical protocols
Standard treatment of postoperative hypoparathyroidism according to the Clinical protocols
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Decreased PTH concentrations in blood serum
* The patient can read, understand, follow the examination procedures and complete, if necessary, the required documentation
* Written informed consent
Exclusion Criteria
* Acute or chronic diseases in the stage of decompensation
* Chronic infectious diseases: HIV, viral hepatitis B, C, tuberculosis
* Patients who are pregnant, breastfeeding, or fertile patients who are not using adequate contraceptive methods
* Chronic and protracted mental disorders, all diseases with the presence of the syndrome of dependence on alcohol, drugs and psychoactive substances, any other condition that makes the patient unable to understand the nature, extent and possible consequences of the study or, in the opinion of the researcher, prevents the patient from observing and performing protocol
* Patients are unable or unwilling to give written informed consent and / or follow research procedures
* Any other medical condition that, in the opinion of the investigator, may be associated with an increased risk to the patient or may affect the outcome or evaluation of the study
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Belarusian State Medical University
OTHER
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrei Hancharou, Dr
Role: STUDY_DIRECTOR
the Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Stanislav Treatiak, Prof
Role: STUDY_DIRECTOR
Belarusian State Medical University
Andrei Bolshov, Dr
Role: PRINCIPAL_INVESTIGATOR
Belarusian State Medical University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IBCE_Parathyr
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.